Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Pharmaceutical Name Gearing Up for Earnings
02:37pm, Tuesday, 28'th Jan 2025
Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due out before the open Wednesday, Jan. 29.
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
01:33pm, Tuesday, 28'th Jan 2025
Piper Sandler analyst David Amsellem reiterated the Overweight rating on Teva Pharmaceutical Industries Limited TEVA with a price forecast of $30.
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for
Top 4 Immunology Stocks Poised For Growth In 2025
04:54pm, Sunday, 19'th Jan 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to
Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
02:00pm, Monday, 13'th Jan 2025
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Company Participants Richard Francis - President and CEO Eric Hughes - He
Teva Pharmaceuticals CEO talks Trump and US healthcare
01:03pm, Monday, 13'th Jan 2025
Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Seana Smith and Madison Mills on Catalysts to discuss what both the pharmace
Teva CEO on Drug Pricing, Generics, Supply Shortages
10:35am, Monday, 13'th Jan 2025
Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market, supply shortages of the drug Adderall, and selling GLP-1 drugs. He speaks
TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) today announced that it has ente
INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies have
Duvakitug And Teva's Growth: A Game Changer In Pharma
03:21pm, Friday, 27'th Dec 2024
On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis. However, a mo
Over the last two years, there hasn't been a hotter trend on Wall Street than the rise of artificial intelligence (AI). The ability for AI-powered software and systems to become more proficient at the
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:30pm, Monday, 23'rd Dec 2024
TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43rd A
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
02:29pm, Wednesday, 18'th Dec 2024
Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
09:25am, Wednesday, 18'th Dec 2024
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
